You are visiting a website that is not intended for your region

The page or information you have requested is intended for an audience outside the United States. By continuing to browse you confirm that you are a non-US resident requesting access to this page or information.

Switch to the US site

News

Resolutions at Getinge’s Extraordinary General Meeting

August 15, 2017 Gothenburg, Sweden

Resolutions at Getinge’s Extraordinary General Meeting

At the Extraordinary General Meeting of Getinge AB held on August 15, 2017, the following was resolved.

Amendment of the Articles of Association

The Meeting resolved in accordance with the Board’s proposal regarding amendment of the Articles of Association by including a conversion provision entailing that a shareholder of share of Series A may on request convert such share to a share of Series B. The request of conversion shall be addressed to the Board and the company shall without delay notify the conversion to the Swedish Companies Registration Office for registration.

Authorisation to resolve on issue of new shares

The Meeting resolved in accordance with the Board’s proposal to authorise the Board of Directors to resolve on the issue of new shares with preferential right for the company’s shareholders during the period up to the company’s Annual General Meeting 2018. The total number of shares that may be issued by virtue of the authorisation shall amount to the number of shares corresponding to issue proceeds of approximately SEK 4 billion, and shall be within the limits of the share capital.

For further information, please contact:

Jeanette Hedén Carlsson 
Executive Vice President Communications & Brand Management
Phone: +46 (0)10 335 1003                                
E-mail: jeanette.hedencarlsson@getinge.com    

Lars Mattsson
Head of Investor Relations
Phone: +46 (0)10 335 0043
E-mail: lars.mattsson@getinge.com


About Getinge
Getinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our firsthand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people - today and tomorrow.

Share: